Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation

Ichidai Tanaka; Masahiro Morise; Ayako Miyazawa; Yuta Kodama; Yutaro Tamiya; Soei Gen; Akira Matsui; Tetsunari Hase; Naozumi Hashimoto; Mitsuo Sato; Yoshinori Hasegawa

doi:10.1016/j.cllc.2020.01.011

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation

Ichidai Tanaka
, Masahiro Morise
, Ayako Miyazawa
, Yuta Kodama
, Yutaro Tamiya
, Soei Gen
, Akira Matsui
, Tetsunari Hase
, Naozumi Hashimoto
, Mitsuo Sato
, Yoshinori Hasegawa

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

To investigate the clinical benefits of bevacizumab plus cytotoxic chemotherapy in lung cancer patients with EGFR mutation, we retrospectively assessed clinical data of 159 subjects. The use of the standard chemotherapy with bevacizumab provided better clinical benefit to patients with EGFR mutation than wild-type carriers.

Original language	English
Pages (from-to)	273-280.e4
Journal	Clinical Lung Cancer
Volume	21
Issue number	3
DOIs	https://doi.org/10.1016/j.cllc.2020.01.011
Publication status	Published - 05-2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/j.cllc.2020.01.011

Cite this

Tanaka, I., Morise, M., Miyazawa, A., Kodama, Y., Tamiya, Y., Gen, S., Matsui, A., Hase, T., Hashimoto, N., Sato, M., & Hasegawa, Y. (2020). Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation. Clinical Lung Cancer, 21(3), 273-280.e4. https://doi.org/10.1016/j.cllc.2020.01.011

@article{72032d8752384782933e0dff61bf90b5,

title = "Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation",

abstract = "To investigate the clinical benefits of bevacizumab plus cytotoxic chemotherapy in lung cancer patients with EGFR mutation, we retrospectively assessed clinical data of 159 subjects. The use of the standard chemotherapy with bevacizumab provided better clinical benefit to patients with EGFR mutation than wild-type carriers.",

author = "Ichidai Tanaka and Masahiro Morise and Ayako Miyazawa and Yuta Kodama and Yutaro Tamiya and Soei Gen and Akira Matsui and Tetsunari Hase and Naozumi Hashimoto and Mitsuo Sato and Yoshinori Hasegawa",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = may,

doi = "10.1016/j.cllc.2020.01.011",

language = "English",

volume = "21",

pages = "273--280.e4",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier Inc.",

number = "3",

}

Tanaka, I, Morise, M, Miyazawa, A, Kodama, Y, Tamiya, Y, Gen, S, Matsui, A, Hase, T, Hashimoto, N, Sato, M & Hasegawa, Y 2020, 'Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation', Clinical Lung Cancer, vol. 21, no. 3, pp. 273-280.e4. https://doi.org/10.1016/j.cllc.2020.01.011

TY - JOUR

T1 - Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation

AU - Tanaka, Ichidai

AU - Morise, Masahiro

AU - Miyazawa, Ayako

AU - Kodama, Yuta

AU - Tamiya, Yutaro

AU - Gen, Soei

AU - Matsui, Akira

AU - Hase, Tetsunari

AU - Hashimoto, Naozumi

AU - Sato, Mitsuo

AU - Hasegawa, Yoshinori

PY - 2020/5

Y1 - 2020/5

N2 - To investigate the clinical benefits of bevacizumab plus cytotoxic chemotherapy in lung cancer patients with EGFR mutation, we retrospectively assessed clinical data of 159 subjects. The use of the standard chemotherapy with bevacizumab provided better clinical benefit to patients with EGFR mutation than wild-type carriers.

AB - To investigate the clinical benefits of bevacizumab plus cytotoxic chemotherapy in lung cancer patients with EGFR mutation, we retrospectively assessed clinical data of 159 subjects. The use of the standard chemotherapy with bevacizumab provided better clinical benefit to patients with EGFR mutation than wild-type carriers.

UR - https://www.scopus.com/pages/publications/85079864583

UR - https://www.scopus.com/pages/publications/85079864583#tab=citedBy

U2 - 10.1016/j.cllc.2020.01.011

DO - 10.1016/j.cllc.2020.01.011

M3 - Article

C2 - 32088115

AN - SCOPUS:85079864583

SN - 1525-7304

VL - 21

SP - 273-280.e4

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 3

ER -

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this